Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Pyxis Oncology Q3 2026 Results: Net Loss of $20M, Loss Narrows

Pyxis Oncology reported a net loss of $68.6 million for the nine months ended September 30, 2026, compared to $61.5 million in the prior year. The company remains in the clinical stage, heavily dependent on its lead product candidate micvotabart pelidotin (MICVO), and recently completed a private placement of common stock to raise approximately $48.3 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-20.0-22.0
Net income-20.0-22.0
EPS (diluted, $ a share)$-0.24$-0.35

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: PYXS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Pyxis Oncology, Inc.: key numbers

Share price
$1.41Close, Nov 16
Market cap
$169M
Shares outstanding
119.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Pyxis Oncology, Inc.

All →
4:18 PM ET 8-K
Other 8-K Filing

Pyxis Oncology Other 8-K Filing

Pyxis Oncology stockholders approved an amendment to the company's Certificate of Incorporation to double the number of authorized shares of common stock from 190 million to 380 million. The amendment became effective upon filing with the Secretary of State of Delaware on November 13, 2026. No shares were issued or sold as part of this filing, which primarily serves to reserve capacity for future corporate purposes.

7:40 AM ET 8-K
Financial Results

Pyxis Oncology Financial Results

Pyxis Oncology reported financial results for the third quarter of 2026, ending the period with $114.3 million in cash and equivalents. The company highlighted progress on its lead candidate, micvotabart pelidotin (MICVO), including alignment with the FDA and EMA on the design of a global Phase 3 trial in head and neck cancer planned for mid-2027.

Term
Q3 2026

“The September monotherapy data reinforce our confidence in MICVO’s potential to serve a significant population of patients with previously treated recurrent/metastatic head and neck cancer. We have aligned with feedback received from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the design of the global Phase 3 Headliner trial and plan to initiate it in mid-2027, with FDA feedback on dose selection expected in the first quarter of 2027.”

Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology
5:25 PM ET 8-K
Capital Raise

Pyxis Oncology Capital Raise of $110M

Pyxis Oncology closed an underwritten public offering of 36,047,919 shares of common stock and pre-funded warrants, along with accompanying common warrants, at a combined price of $2.90 per share. The offering raised approximately $110 million in gross proceeds before expenses. The common warrants will only become exercisable upon stockholder approval of a charter amendment to increase the company's authorized share count.

Value
$110M
Counterparty
Leerink Partners LLC, Guggenheim Securities, LLC and Wells Fargo Securities, LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.